KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Gregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Maria Luisa Peña-Peña, Roberto Barriales-Villa, Ozlem Bilen, Melissa Burroughs, Brian Claggett, Juan Pablo Costabel, Edileide de Barros Correia, Anne M Dybro, Ian J Kulac, Neal K Lakdawala, Amy Mann, Martin S Maron, Shaina McGinnis, Ajith Nair, Chloe Newlands, Steen H Poulsen, Patricia Reant, P Christian Schulze, Scott D Solomon, Andrew Wang, Regina Sohn, Indrias Berhane, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer, Fady I Malik, Amy Wohltman, Michael A Fifer, Perry M Elliott, MAPLE-HCM Investigators

JAMA Cardiol e261730

PMID42307914
PMCIDPMC13276672
DOI10.1001/jamacardio.2026.1730
发表日期2026-06-17
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线。
摘要

摘要

IMPORTANCE: Patients with obstructive hypertrophic cardiomyopathy (oHCM) endure life-altering exercise limitations. Current treatment guidelines recommend β-blockers as first-line therapy primarily based on expert opinion. The Metoprolol vs Aficamten in Patients with Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCM (MAPLE-HCM) trial characterizes comprehensive exercise response to aficamten monotherapy vs β-blockade (metoprolol). OBJECTIVE: To determine the effect of aficamten compared with metoprolol across all stages of exercise using 16 quantitative measures in individuals with oHCM. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the MAPLE-HCM study, a phase 3, randomized, active-control trial conducted from June 2023 to March 2025 with data analyzed between May and July 2025 at 71 sites in North America, South America, Europe, Israel, and China. Patients with symptomatic oHCM with objective evidence of exercise intolerance (peak oxygen uptake [pVO2] <100% of predicted) were included. Those with a history of atrial fibrillation (paroxysmal or persistent), medical indication for β-blockers or calcium channel blockers prohibiting drug discontinuation, or intolerance or medical contraindication to β-blockers were excluded. INTERVENTION: Randomized 1:1 to titrated aficamten (5-20 mg daily) or matching titrated metoprolol (50-200 mg daily) for 24 weeks. MAIN OUTCOMES AND MEASURES: The main outcomes were submaximal exercise minute ventilation (VE)/carbon dioxide output (VCO2) slope and anaerobic threshold; peak exercise duration, workload, heart rate and heart rate reserve; and postexercise oxygen recovery rates; and composite variables, such as circulatory power. RESULTS: Of 175 randomized participants (mean [SD] age, 57.7 [13.2] years; 102 [58.3%] male), 165 (94%) had core laboratory-validated exercise tests at baseline and week 24. Compared with metoprolol, aficamten treatment improved multiple stages of exercise; including submaximal exercise VE/VCO2 slope (-2.8; 95% CI, -4.0 to -1.5; P < .001) and anaerobic threshold (76 mL/min; 95% CI, 41 to 111; P < .001); peak workload (8 watts; 95% CI, 3 to 13; P = .003); the time required for VO2 to recover by 12.5% postexercise (-11 seconds; 95% CI, -16 to -5; P < .001); and circulatory power (819 mm Hg × mL/min per kg; 95% CI, 569 to 1070; P < .001). Large improvements (≥3.0 mL/kg/min) in peak VO2 were more common with aficamten compared with metoprolol (17 [20.5%] vs 3 [3.7%], respectively; odds ratio, 6.8; 95% CI, 2.0 to 22.5; P < .001). In contrast, large reductions in peak VO2 (≥3.0 mL/kg/min) were significantly more common with metoprolol than aficamten (17 [20.7%] vs 2 [2.4%], respectively; odds ratio, 10.6; 95% CI, 2.6 to ∞; P < .001). CONCLUSIONS AND RELEVANCE: This prespecified analysis of MAPLE-HCM demonstrated monotherapy with aficamten was superior to metoprolol in promoting adaptation to multiple phases of exercise in patients with symptomatic oHCM and supports aficamten as first-line therapy for oHCM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05767346.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Bar Graph Showing Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVO 2 ) With Aficamten vs Metoprolol at 24 Weeks Data represented as proportion of participants experiencing small (0 to < 1.5), moderate (≥1.5 to < 3), or large (≥3.0) improvements or deteriorations in pVO 2 (mL/kg/min), per treatment group. NNH indicates number needed to harm with metoprolol as the reference group; NNT indicates number needed to treat with aficamten as the reference group; OR, odds ratio.
非 KM Figure
Figure 2Figure 2.. Cubic Spline Graphs Showing the Correlation Between Change in Peak Oxygen Uptake (pVO 2 ) and Clinical Metrics Change in KCCQ-CSS (A), NYHA functional class (B), resting LVOT-G (C), and Valsalva LVOT-G (D) in relation to change in pVO 2 from baseline to 24 weeks. Linear regression with cubic terms. Analyses adjusted for baseline values of both parameters. Solid lines and shading show the association correlate with 95% CIs. Histograms show the distribution of change in pVO 2 . KCCQ-CSS indicates Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score; LVOT-G, left ventricular outflow tract gradient; NYHA, New York Heart Association; pVO 2 , peak oxygen uptake.
非 KM Figure
Figure 3Figure 3.. Cubic Spline Graphs Showing the Correlation Between Changes in Peak Oxygen Uptake (pVO 2 ) and Component Variables of pVO 2 as Well as Biomarkers Change in pVO 2 component variables, peak O 2 pulse (A), and peak heart rate (B) in relation to change in pVO 2 from baseline to 24 weeks as well as change in pVO 2 relative to change in N-terminal pro–B-type natriuretic peptide (NT-proBNP) (C) and high-sensitivity cardiac troponin I (hs-cTnI) (D). Linear regression with cubic terms. Analyses adjusted for baseline values of both parameters. Solid lines and shading show the association correlate with 95% CIs. Histograms show the distribution of change in pVO 2 .
非 KM Figure